touchENDOCRINOLOGY An Update On The Hypoglycaemia-Hyperglycaemia Minimizer System In The Management Of Type 1 Diabetes
LONDON, April 21, 2016 /PRNewswire/ --
Brian L Levy, et al. European Endocrinology, 2016;12(1):18-23 http://doi.org/10.17925/EE.2016.12.01.18
(Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO )
Published recently in European Endocrinology, the peer-reviewed journal from touchENDOCRINOLOGY, Brian Levy et al discusses how living with type 1 diabetes (T1D) presents many challenges in terms of daily living. Insulin users need to frequently monitor their blood glucose levels and take multiple injections per day and/or multiple boluses through an insulin infusion pump, with the consequences of failing to match the insulin dose to the body's needs resulting in hypoglycaemia and hyperglycaemia. The former can result in seizures, coma and even death; the latter can have both acute and long-term health implications. Many patients with T1D also fail to meet their treatment goals. In order to reduce the burdens of self-administering insulin, and improve efficacy and safety, there is a need to at least partially remove the patient from the loop via a closed-loop 'artificial pancreas' system. The Hypoglycaemia-Hyperglycaemia Minimizer (HHM) System, comprising a continuous, subcutaneous insulin infusion pump, continuous glucose monitor (CGM) and closed-loop insulin dosing algorithm, is able to predict changes in blood glucose and adjust insulin delivery accordingly to help keep the patient at normal glucose levels. Early clinical data indicate that this system is feasible, effective and safe, and has the potential to dramatically improve the therapeutic outcomes and quality of life for people with T1D.
The full peer-reviewed, open-access article is available here:
http://doi.org/10.17925/EE.2016.12.01.18
Disclosure: Brian L Levy, Thomas W McCann, Jr and Daniel A Finan are employees of Animas Corporation
Note to the Editor
touchENDOCRINOLOGY (a division of Touch Medical Media) publishes
European Endocrinology, a peer-reviewed, open access, bi-annual journal specialising in the publication of balanced and comprehensive review articles written by leading authorities to address the most important and salient developments in the field of endocrinology. The aim of these reviews is to break down the high science from 'data-rich' primary papers and provide practical advice and opinion on how this information can help physicians in the day to day clinical setting. Practice guidelines, symposium write-ups, case reports, and original research articles are also featured to promote discussion and learning amongst physicians, clinicians, researchers and related healthcare professionals.
http://www.touchENDOCRINOLOGY.com
For inquires please contact:
Carla Denaro - Managing Editor
managingeditor@touchmedicalmedia.com
Providing practical opinion to support best practice for busy healthcare professionals.
(Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO )
Published recently in European Endocrinology, the peer-reviewed journal from touchENDOCRINOLOGY, Brian Levy et al discusses how living with type 1 diabetes (T1D) presents many challenges in terms of daily living. Insulin users need to frequently monitor their blood glucose levels and take multiple injections per day and/or multiple boluses through an insulin infusion pump, with the consequences of failing to match the insulin dose to the body's needs resulting in hypoglycaemia and hyperglycaemia. The former can result in seizures, coma and even death; the latter can have both acute and long-term health implications. Many patients with T1D also fail to meet their treatment goals. In order to reduce the burdens of self-administering insulin, and improve efficacy and safety, there is a need to at least partially remove the patient from the loop via a closed-loop 'artificial pancreas' system. The Hypoglycaemia-Hyperglycaemia Minimizer (HHM) System, comprising a continuous, subcutaneous insulin infusion pump, continuous glucose monitor (CGM) and closed-loop insulin dosing algorithm, is able to predict changes in blood glucose and adjust insulin delivery accordingly to help keep the patient at normal glucose levels. Early clinical data indicate that this system is feasible, effective and safe, and has the potential to dramatically improve the therapeutic outcomes and quality of life for people with T1D.
The full peer-reviewed, open-access article is available here:
http://doi.org/10.17925/EE.2016.12.01.18
Disclosure: Brian L Levy, Thomas W McCann, Jr and Daniel A Finan are employees of Animas Corporation
Note to the Editor
touchENDOCRINOLOGY (a division of Touch Medical Media) publishes
European Endocrinology, a peer-reviewed, open access, bi-annual journal specialising in the publication of balanced and comprehensive review articles written by leading authorities to address the most important and salient developments in the field of endocrinology. The aim of these reviews is to break down the high science from 'data-rich' primary papers and provide practical advice and opinion on how this information can help physicians in the day to day clinical setting. Practice guidelines, symposium write-ups, case reports, and original research articles are also featured to promote discussion and learning amongst physicians, clinicians, researchers and related healthcare professionals.
http://www.touchENDOCRINOLOGY.com
For inquires please contact:
Carla Denaro - Managing Editor
managingeditor@touchmedicalmedia.com
Providing practical opinion to support best practice for busy healthcare professionals.